Geneva, Switzerland, April 21, 2020 – Selexis SA, a JSR Life Sciences Company, announced today that Great Place to Work® has recognized the Company as one of the “Best Workplaces in Switzerland 2020.” Selexis joins companies of all sizes from all industries whose employees think they have an especially trustworthy, appreciative and attractive workplace culture. Selexis also earned the distinction in 2018 and 2019.
“Our people are why Selexis is a Great Place to Work,” said Igor Fisch, PhD, Selexis chief executive officer. “We learned about our certification this year during unprecedented times brought on by a global public health crisis. Over the past month and a half, our employees adapted to extraordinary changes in our operations and in our working environment while continuing to care for each other. While they prioritized themselves and their families, they also helped ensure Selexis’ business continuity and the important work of our biopharmaceutical partners. I am extremely grateful for all they have done.”
In the employee satisfaction questionnaire, 93% of Selexis employees agreed with the statement: "Taking everything into account, I would say this is a great place to work." Additionally, 96% of Selexis employees agreed they “care about each other, are willing to give extra to get the job done, feel the company is a friendly place to work and are made to feel welcome,” while 98% indicated “I’m proud to tell others I work here.”
The research institute analyzes a company’s attractiveness through a two-step process. First, Selexis employees are surveyed anonymously on central workplace topics such as trust, identification, team spirit, professional development, remuneration, health support and work-life balance. Second, the company’s HR processes and corporate culture are audited by peers. Scores from the survey and the culture audit were used to rank the winners.
“Great Place to Work evaluates the ‘Best Workplaces in Switzerland’ based on the quality of the workplace culture. In various studies, we have been able to show that workplace culture is directly related to employee turnover rates and employee commitment, but also to the financial results of organizations,” said Dr. Thomas Schneider, co-owner and consultant at Great Place to Work Switzerland. “So in various areas it pays to be one of the best employers in Switzerland - employees enjoy working for excellent employers and are productive.”
About Great Place to Work Switzerland
As an international consulting company with offices in over 60 countries, Great Place to Work helps organizations develop an excellent workplace culture. In Switzerland, Great Place to Work was founded in 2008 and has offices in Zurich and Lausanne. Great Place to Work uses a globally established model with evidence-based standards to analyze workplace culture. Organizations with an excellent workplace culture are successfully able to activate the potential of all their employees and thus increase value creation. The basis for this is mutual trust, lived values and leadership quality.
The strengths and potential of the workplace culture are evaluated on the basis of an employee survey and a culture audit and further developed through concrete measures. This approach shows both the influence on value creation and enables a comparison with other organisations.
This is how the basis for the Great Place to Work "Best Workplaces" award as well as for the "Great Start!" certification of the Swiss training companies is created.
Every year, Great Place to Work Switzerland evaluates the workplace culture of more than 100 organisations - from SMEs to large companies - and thus supports them in their development into attractive employers. You can find more information on: https://en.greatplacetowork.ch/.
About Selexis SA
Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
FOR MORE INFORMATION
Media Inquiries for Selexis
Sam Brown Inc.
Company Inquiries for Selexis
Head, Corporate Communications